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Summary 
Progesterone receptor (PR) expression is employed as a biomarker of estrogen 
receptor-  (ER ) function and breast cancer prognosis. We now show that PR is 
not merely an ER -induced gene target, but is also an ER -associated protein 
that modulates its behaviour. In the presence of agonist ligands, PR associates 
with ER  to direct ER  chromatin binding events within breast cancer cells, 
resulting in a unique gene expression programme that is associated with good 
clinical outcome. Progesterone inhibited estrogen-mediated growth of ER+ cell 
line xenografts and primary ER+ breast tumour explants and had increased 
anti-proliferative effects when coupled with an ER  antagonist. Copy number 
loss of PgR is a common feature in ER+ breast cancers, explaining lower PR 
levels in a subset of cases. Our findings indicate that PR functions as a molecular 
rheostat to control ER  chromatin binding and transcriptional activity, which 
has important implications for prognosis and therapeutic interventions. 
 
There is compelling evidence that inclusion of a progestogen as part of hormone 
replacement therapy (HRT) increases risk of breast cancer, implying that PR 
signalling can contribute towards tumour formation1. However, the increased risk of 
breast cancer associated with progestogen-containing HRT is mainly attributed to 
specific synthetic progestins, in particular medroxyprogesterone acetate (MPA), 
which is known to also have androgenic properties2. The relative risk is not 
significant when native progesterone is used3. In ER+ breast cancers, PR is often 
used as a positive prognostic marker of disease outcome4, but the functional role of 
PR signalling remains unclear. While activation of PR may promote breast cancer in 
some women and in some model systems, progesterone treatment has been shown to 
be antiproliferative in ER+ PR+ breast cancer cell lines5-7 and progestogens have 
been shown to oppose estrogen-stimulated growth of an ER+ PR+ patient-derived 
xenograft8. In addition, exogenous expression of PR in ER+ breast cancer cells 
blocks estrogen-mediated proliferation and ER transcriptional activity9. Furthermore, 
in ER+ breast cancer patients, PR is an independent predictor of response to 
adjuvant tamoxifen10, high levels of PR correlate with decreased metastatic events in 
early stage disease11 and administration of a progesterone injection prior to surgery 
can provide improved clinical benefit12. These observations imply that PR activation 
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in the context of estrogen-driven, ER+ breast cancer, can have an anti- tumourigenic 
effect. In support of this, PR agonists can exert clinical benefit in ER+ breast cancer 
patients that have relapsed on ER antagonists13. 
 
Breast cancers are typically assessed for ER, PR and HER2 expression to define 
histological subtype and guide treatment options. PR is an ER-induced gene14 and 
ER+ PR+ HER2- tumours tend to have the best clinical outcome because PR 
positivity is thought to reflect a tumour that is driven by an active ER complex and 
therefore likely to respond to endocrine agents such as tamoxifen or aromatase 
inhibitors10,15. While ER+ PR+ tumours have a better clinical outcome than ER+ 
PR- tumours4, clinical response to ER antagonists can vary, even among tumours 
with similar ER and PR status15,16 and recent evidence suggests that PR may be 
prognostic, but not predictive17.  Some ER+ PR- tumours that are resistant to one 
class of ER antagonists gain clinical benefit from another class, suggesting that in a 
subset of ER+ PR- breast cancers, the lack of PR expression does not reflect a non-
functional ER complex. It has been proposed that the non-functional ER complex 
theory cannot completely explain PR negativity18. An alternative hypothesis is that 
other factors contribute to the loss of PR expression, which consequently influences 
breast tumour responses to ER target therapies.  
 
PR is recruited to the ER  complex  
Given the controversial and complex interplay between the ER and PR pathways in 
breast cancer, we explored the possible functional crosstalk between these two 
transcription factors and the implications for clinical prognosis in ER+ disease. 
Ligand-activated ER and PR protein complexes were purified to ascertain interplay 
between these two transcription factors. Asynchronous ER+ PR+ MCF-7 and T-47D 
breast cancer cells were grown in SILAC-labelled growth media, which contains 
sufficient estrogen to elicit maximal ER binding to chromatin19. Estrogen treatment 
is required to induce detectable levels of PR in MCF-7 cells but not T-47D cells20. 
The two cell lines were subsequently treated with vehicle or one of two progestogens: 
native progesterone or the synthetic progestin R5020. Cells were cross- linked 
following hormone treatment and endogenous PRwas immunopurified followed by 
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mass spectrometry, using a technique we recently developed called RIME21. Under 
estrogenic conditions, progesterone treatment significantly induced an interaction 
between PR and ER in the MCF-7 and T-47D cell lines, in support of previous 
findings showing a physical interaction between these two nuclear receptors22. In 
addition to ER, progesterone treatment induced interactions between PR and known 
ER-associated co-factors, including NRIP1, GATA3 and TLE321 in both cell lines 
(Figure 1a).  As expected, treatment with natural ligand decreased interaction between 
PR and chaperone/co-chaperone proteins such as HSP90 and FKBP4/5 (Figure 1a). 
The same findings were observed when R5020 was used as a synthetic ligand 
(Extended data figure 1). Interestingly, when ER was purified under the same 
treatment conditions, PR was the only differentially recruited protein in both cell lines 
(Figure 1b). Moreover, the interaction between ERand known ER-associated co-
factors was not differentially affected by progesterone treatment. A list of all 
interacting proteins under all experimental conditions is provided in Supplementary 
table 1. The progesterone- induced ER-PR interaction was confirmed by standard co-
IP experiments in both MCF-7 and T-47D cells (Figure 1c). We conclude that 
activation of PR results in a robust association between PR and the ER complex. 
However, it remains unclear what impact this may have on ER/PR DNA binding or 
what the primary DNA tethering mechanism may be (Figure 1d). 
 
Progesterone reprograms ER  binding events  
Since PR is a transcription factor, we hypothesised that the progestogen-induced 
interaction between PR and ER alters chromatin binding properties of the ER-co-
factor complex. MCF-7 and T-47D cell lines grown in complete (estrogenic) media 
were stimulated with progesterone, R5020 or vehicle control for 3 or 24 hours, 
followed by analysis of genome-wide ER and PR and the co-activator p300 profiles 
by ChIP-seq. p300 deposits the H3K27Ac mark, which is indicative of functional 
enhancers23. We found comparable ER, PR and p300 binding at 3 hours and 24 
hours (Extended data figure 1 and data not shown) and chose 3hr for the remaining 
experiments. All ChIP-seq experiments were subsequently repeated in triplicate 
following 3 hours of treatment (sample clustering is provided in Extended data figure 
2). Whereas robust ER binding (29,149 sites in MCF-7 cells and 8,438 sites in T-
47D cells) was observed in estrogenic conditions, limited PR binding events were 
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seen under these conditions (Supplementary table 2). Treatment with progesterone or 
the synthetic progestin R5020 in estrogen-rich media resulted in robust PR 
recruitment to chromatin, with 46,191 PR binding events observed in T-47D cells 
with both ligands and 29,554 PR binding events in MCF-7 cells. Using DiffBind to 
identify differential peaks24 that occurred following treatment of cells with 
progesterone or R5020, a rapid and robust redistribution of ER binding to novel 
genomic loci was observed (Figure 2a and 2b). In T-47D cells, 14,223 ER binding 
events were reproducibly gained following 3 hours of treatment with progesterone, a 
finding that was similar following stimulation with R5020, confirming a predictable 
redistribution of ER chromatin binding following stimulation of the PR pathway. A 
similar rapid redirection of ER was observed in MCF-7 cells after progesterone or 
R5020 treatment (Extended data figure 1). The ER sites reprogrammed by 
progesterone are likely to be functional, as indicated by the global recruitment of the 
co-activator p300 (Figure 2b and Extended data figure 2). These ER binding events 
appear to be mediated by PR, since 99% of the gained ER binding sites in T-47D 
cells overlapped with a PR binding event (Figure 2c) (the overlap in MCF-7 cells was 
94%) and motif analysis of the ER gained sites revealed the presence of 
progesterone responsive elements (PREs), but not estrogen responsive elements 
(EREs) (Figure 2b). This suggests that PR mediates the interaction between the 
ER/PR/p300 complex and DNA. ER ChIP-seq was repeated in MCF-7 and T-47D 
cells following hormone deprivation and subsequent treatment with vehicle, estrogen 
alone or progesterone alone. Single hormone treatments did not induce the ER 
binding events observed under dual hormone conditions (Extended data figure 3), 
confirming that the ER reprogramming is dependent on having both receptors 
activated simultaneously. In addition, Forkhead motifs were enriched at the ER 
gained sites and 49% of the gained ER/PR binding events were shown to overlap 
with FoxA1 binding (Extended data figure 4), consistent with previous findings 
showing that PR binding involves the pioneer factor FoxA125. In keeping with the 
anti-proliferative effects of progestogens in ER+ breast cancer cells, analysis of the 
genes bound by ER following progesterone treatment revealed enrichment for cell 
death, apoptosis and differentiation pathways (Supplementary table 3).  
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To identify the transcriptional targets of the progestogen- induced ER binding events, 
we treated estrogen-stimulated MCF-7 and T-47D cells with progesterone, R5020 or 
vehicle for 3 hours and performed eight replicates of RNA-seq. In total, 470 genes 
were differentially regulated by dual treatment with estrogen and progesterone or 
R5020 compared to estrogen alone in both T-47D and MCF7 cell lines (Extended data 
figure 4). GSEA analysis revealed a pronounced enrichment of progestogen-induced 
ER binding events near genes up-regulated by progestogen treatment in the presence 
of estrogen (Figure 2d). Collectively, these findings suggest that the progestogen-
mediated changes in ER binding events are functionally significant, since they co-
recruit p300 and lead to new gene expression profiles (Figure 2d and Extended data 
figure 4). Importantly, increased expression of a gene signature that results from 
progesterone-stimulated ER binding confers good prognosis in a cohort of 1,959 
breast cancer patients (Extended data figure 5). 
 
The relative degree of ER reprogramming and gene expression changes following 
progesterone treatment was higher in T-47D cells compared to MCF-7 cells 
(Supplementary table 2), possibly due to the differences in PR levels between these 
two cell lines20. We assessed the PR gene (PgR) in these cell lines, which revealed 
copy number gain of the PgR gene in T-47D cells and a heterozygous loss of the PgR 
gene in MCF-7 cells (Extended data figure 5). Exogenous expression of PR (both 
isoforms) in the MCF-7 cell line resulted in growth inhibition (Extended data figure 
6), confirming an anti-proliferative role for PR, via modulation of ER transcriptional 
activity9.  
 
Progesterone blocks ER  tumour growth 
To explore the hypothesis that progesterone stimulation could have beneficial effects 
on ERtumour growth in vivo, we established MCF-7-Luciferase xenografts in 
NOD/SCID/IL2Rg-/- (NSG) mice and exposed the mice to control (i.e. no hormone), 
slow release estrogen pellets or slow release estrogen plus standard high concentration 
progesterone pellets26. Ten tumours for each condition were implanted (two tumours 
per mouse and five mice per condition) and tumour formation was monitored using 
bioluminescent imaging. After 25 days, in the absence of any hormone, tumours did 
not grow, but stimulation with estrogen alone resulted in tumour growth. Co-
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treatment with estrogen plus progesterone resulted in a significant decrease in tumour 
volume, as compared to estrogen alone, when measured by bioluminescence (Figure 
3a and 3b) (p = 0.0021) or tumour volume (p = 0.019) (Extended data figure 6). 
Immunohistochemistry confirmed that PR expression was induced under both 
estrogen and estrogen plus progesterone conditions (Extended data figure 7), but 
importantly, PR will only be active under dual hormone conditions. We repeated the 
MCF-7 xenograft experiment in ovariectomised mice, in order to eliminate any 
confounding issues related to endogenous mouse hormones. Assessment of tumour 
growth (Extended data figure 7) confirmed the previous finding (Figure 3b) that 
progesterone inhibited tumour formation. We performed ER and PR ChIP-seq on six 
randomly selected sets of matched estrogen or estrogen plus progesterone stimulated 
xenograft tumours (taken from the final time point) and identified differentially bound 
ER binding events. The major variable driving clustering of ER binding events 
within tumour xenografts was the treatment condition (Extended data figure 7). As 
observed in the short-term cell line experiments (Figure 2), estrogen-stimulated ER 
binding in the xenograft tumours was substantially altered by progesterone treatment. 
We observed 3,603 differentially regulated ER binding events in xenograft tumours 
from estrogen plus progesterone conditions, when compared to estrogen-only 
conditions (Figure 3c). As such, progesterone induced a global reprogramming of 
ER binding events in vivo, even following long-term hormonal treatment. 
 
To extend our findings into primary tumours, we employed a novel ex vivo primary 
tumour culture system27,28 to cultivate ER+ PR+ primary tumours for short time 
periods, in order to study the effect of hormonal treatment on cell growth. Fourteen 
independent ER+ PR+ primary tumours were used for the analysis. Each tumour 
was cut into small pieces and randomised onto gelatine sponges half-submersed in 
media to sustain tissue architecture and viability. Tumour explants were then 
cultivated under hormone-deprived conditions for 36 hours, followed by a 48 hour 
treatment with vehicle control, estrogen, the synthetic progestin R5020 or estrogen 
plus R5020. Tumours retained normal cellular and morphological features after 
treatment in the ex vivo context (Extended data figure 8).  Fixed tissues were stained 
for Ki67 to assess changes in proliferation. Most of the tumours responded to estrogen 
with a coincident increase in the percentage of cells that expressed Ki67. Co-
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treatment with progestin significantly inhibited estrogen-stimulated proliferation 
(Figure 3d and Extended data figure 8), showing that progesterone can antagonise 
estrogen- induced growth in primary human breast tumours cultivated as explants. 
Example images are shown in Figure 3e. Importantly, the addition of progestin alone 
did not increase growth rates (Figure 3d and Extended data figure 8), in support of our 
hypothesis that progesterone lacks proliferative potential and importantly, is anti-
proliferative in an estrogen-driven context. ER and PR co- localisation was 
confirmed in the explant tumour samples using immunofluorescence, as was the 
reduction in Ki67 following progestogen treatment (Extended data figure 8). 
 
Given our findings that progestogens are anti-proliferative in an estrogen-driven 
tumour context, we combined progesterone treatment with a standard of care therapy 
in xenograft models. MCF-7 xenografts were implanted in NSG mice and 
supplemented with slow-release estrogen pellets. Mice were subsequently treated with 
vehicle, progesterone alone, tamoxifen alone or progesterone plus tamoxifen and 
tumour growth was monitored. As previously seen (Figure 3b and Extended data 
figure 6), progesterone antagonised estrogen-induced tumour formation, as did 
tamoxifen alone, but the combination of tamoxifen plus progesterone had the grea test 
tumour inhibitory effect (Figure 3f). This experiment was repeated in a second 
xenograft model (T-47D cells), confirming the finding that tumour volume was 
inhibited by progesterone alone, but the greatest degree of tumour inhibition was 
observed under conditions where an ER antagonist (tamoxifen) was coupled with a 
PR agonist (progesterone) (Extended data figure 6).   
 
PgR copy number alterations are common 
Given the PgR copy number loss observed in the MCF-7 cell line (Extended data 
figure 5), we explored whether this was a common phenomenon observed in breast 
cancer patients, by assessing genomic copy number alterations (CNA) within the 
METABRIC cohort of ~2,000 breast cancers29. This analysis revealed that 18.5% of 
all breast cancers possess a copy number loss in the PgR genomic locus and these are 
biased towards ER+ cases (Figure 4a). This level of loss of heterozygosity (LOH) 
has been previously observed at this genomic locus in a small cohort of patients30.  In 
total, 21% of ER+ breast cancers contain a heterozygous or a homozygous deletion 
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of the PgR genomic locus and these tumours had significantly (p < 0.001) lower PR 
mRNA levels (Figure 4b). Importantly, within the 1,484 ER+ cases, tumours with 
copy number loss of the PgR genomic region had a poorer clinical outcome (p = 
0.001) (Figure 4c), suggesting that inactivation of the PgR gene contributes to worse 
outcome within this subset of ERtumours.  
 
ER mRNA levels are significantly higher in tumours with PgR copy number loss 
(Figure 4d). Copy number loss of PgR affects gene expression events, since the 
expression level of genes shown to be progestogen- induced under estrogenic 
conditions in the cell lines was significantly lower (p < 0.001) in tumours with PgR 
copy number loss and, inversely, the expression level of genes repressed by 
progestogens was significantly elevated (p = 0.001) in tumours with an inactivated 
PgR gene (Figure 4e).  
 
Using PAM50 breast cancer subtype stratification, 33% of luminal B tumours 
(typically poor prognosis and PR low/negative) possessed copy number loss of the 
PgR genomic region (Figure 4f), explaining the lower PR protein levels in one third 
of this breast cancer subtype. In addition, even within the luminal A tumours only 
(which tend to have a better outcome), 19% have a copy number loss of PgR and this 
subset of luminal A tumours have a poorer clinical outcome (Extended data figure 9). 
Tumours were then stratified based on the ten recently described genomic integrative 
clusters29, revealing three ER+ subtypes (int. clusters 1, 2 and 6) with at least 35% 
PgR copy number loss (Figure 4g). All three of these integrative clusters have 
intermediate or poor clinical outcome (Figure 4g). Data showing genomic copy 
number changes on the chromosome 11 arm that encompasses the PgR gene are 
shown in Extended data figure 9. This level of PgR copy number loss was even higher 
in an independent cohort of breast cancer patients: 29% of luminal (ER+) breast 
cancers from TCGA31 (Extended data figure 10). Within luminal B tumours only, 
39% of TCGA breast cancer cases had a PgR copy number loss.  
 
Our data show that PR and ER are functionally linked in breast cancer cells with a 
greater complexity than previously recognised. Good prognosis luminal A ER+ PR+ 
breast tumours, when exposed to both estrogens and progestogens, have an ER 
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chromatin binding profile that is dictated by PR binding events. The functional 
significance of this steroid receptor crosstalk is regulation of a gene expression 
program associated with low tumourigenicity; hence, better disease outcome. 
Genomic alterations in the PgR genomic locus appear to be a relatively common 
mechanism for reduction of PR expression, which may consequently lead to altered 
ER chromatin binding and target gene expression patterns that increase breast 
tumourigenicity and confers a poor clinical outcome. This ER-PR crosstalk may be 
directly influenced by many variables, including the relative receptor levels and the 
hormonal milieu. The presence or absence of estrogen may significantly alter the 
outcome of PR-ER interactions, such that the anti-proliferative effects of PR 
activation may be limited to estrogenic conditions. Our findings show that PR is not 
simply a marker of a functional ER complex18. Rather, we propose that PR is a 
critical determinant of ER function due to crosstalk between PR and ER. In this 
scenario, under estrogenic conditions, an activated PR functions as a proliferative 
brake in ER+ breast tumours by re-directing ER chromatin binding and altering the 
expression of target genes that induce a switch from a proliferative to a more 
differentiated state6.  
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Methods  
Cell lines and SILAC labeling of cell lines 
MCF-7 and T-47D human cell lines were obtained directly from ATCC and grown in 
DMEM, supplemented with 10% FBS. All cell lines were regularly genotyped using 
STR profiling using the Promega GenePrint 10 system. Cell lines were regularly 
tested for mycoplasma infection. 
 
Rapid IP-Mass Spectrometry of Endogenous Protein (RIME) 
 12 
Rapid Immuno precipitation-MS experiments were performed as previously 
described21.  MCF-7 and T-47D cells were grown in R/K-deficient SILAC DMEM 
(PAA; E15-086), 10% dialyzed serum (Sigma-Aldrich; F0392), and supplemented 
with 800 mM L-Lysine 
13
C6 
15
N2Hydrochloride and 482 mM L-Arginine 
13
C6 
15
N4 
hydrochloride (Sigma- Aldrich) for ‘heavy’- labeled media or 800 mM L-Lysine 
12
C6 
14
N2-Hydrochloride and 482 mM L-Arginine 
12
C6 
14
N4 hydrochloride for ‘light’-
labeled media. Antibodies used were ER (Santa Cruz - sc-543, lot- A2213) and PR 
(Santa Cruz- sc-7208, lot H2312). 20 µgs of each antibody was used for each RIME 
experiment. 
 
Each RIME experiment was performed by mixing 20 million cells from each label 
after respective drug treatments. Cells were treated with either progesterone (100 nM), 
R5020 (10 nM) or vehicle (ethanol).  Two replicates of each experiment was 
performed and the results were validated by switching the SILAC labels. The RIME 
method, Mass spectrometry and data analysis were performed as previously 
described21. 
 
Western Blot and Co-Immunoprecipitation 
Immunoprecipitation experiments for ER and PR were performed using Santa Cruz 
antibodies. Antibodies used were ER (sc-543) and PR (sc-7208). Western blots for 
ER and PR were performed using Novocastra antibodies (ERNCL-L-ER6F11 
and PR: NCL-L-PGR-AB). 
 
ChIP-seq 
ChIP-seq experiments were performed as described32. Antibodies used are ER 
(Santa Cruz - sc-543, lot- A2213), PR (Santa Cruz- sc-7208, lot H2312) and p300 
(Santa Cruz sc-585, lot –E2412). 10 µg of antibody was used for each experiment. 
Cells were treated with either progesterone (100 nM), R5020 (10 nM) or vehicle 
(ethanol) and experiment was performed in triplicates.  
 
For xenograft experiments, ER ChIP-seq experiments were performed from six sets 
of randomly chosen tumours under estrogen only or progesterone and estrogen 
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treatment condition. Also included were two tumours from vehicle (control) 
conditions. 
 
ChIP-seq data analysis  
Statistical tests and cutoffs were selected based on published recommendations24. 
 
RNA-seq 
RNA-Sequencing experiments were performed in MCF-7 and T-47D cells. Cells were 
treated with progesterone (100 nM) or R5020 (10 nM) for 3 hours and RNA extracted. 
Experiment was performed in eight replicates for each cell line. 
 
RNA-seq analysis 
Single-end 40bp reads generated on the Illumina HiSeq sequencer were aligned to the 
human genome version GRCh37.64 using TopHat v2.0.433. Read counts were then 
obtained using HTSeq-count v0.5.3p9 (http://www-
huber.embl.de/users/anders/HTSeq/doc/overview.html). Read counts were then 
normalised and tested for differential gene expression using the DESeq34 workflow. 
Multiple testing correction was applied using the Benjamini-Hochberg method. Genes 
were selected as differentially expressed such that FDR <0.01.  
 
GSEA analysis 
Integration of the RNA-Seq data and the ChIP-Seq DBA results were carried out 
using Gene Set Enrichment Analysis (GSEA)35 as follows. All genes assessed by 
RNA-Seq were ranked and weighted by their mean log2 fold change on progesterone 
treatments. Lists of genes that overlapped with regions showing significant 
differential binding on progesterone treatment were derived. These data were then 
analysed using the GSEA v2.0.13 GSEA Preranked tool. 
 
Gene signature analysis 
We derive a prognostic gene signature of consisting of progesterone regulated genes. 
We included genes that were determined by RNA-seq (see above) as differentially up-
regulated in T47-D cells when subjected to progesterone/progestin, as well as having 
a differentially bound ER binding site with increased binding affinity (determined 
using DiffBind) within 10kb of the transcription start site. 38 genes met these criteria 
 14 
(see Extended data figure 5). This signature was validated using the METABRIC 
expression dataset (15), showing that patients in the highest 10% of expression of 
genes in the signature exhibit significantly better breast cancer specific survival than 
patients in the lowest 10% of expression (p=7.36e-04); Extended data figure 5). 
 
As it has been shown that many gene signatures have significant power to predict 
outcome in breast cancer (Venet et al), we subjected the signature to additional 
statistical tests using the Bioconductor package SigCheck (Stark et al). We used 
SigCheck to generate a null distribution of 1,000 signatures consisting of 38 genes 
selected at random, and computed their survival p-values using the survival data for 
the 392 patients with high or low expression over the progesterone induced genes. 
The progesterone induced signature performed in the 99th percentile, with 1.2% of 
random signatures demonstrating an equal or lessor p-value (empirical p-value=0.012; 
Extended data figure 5). Considering previously identified cancer signatures, of the 
189 oncogenic signatures identified in MSigDB (Subramanian et al), 11 had equal or 
lessor p-values, placing the progesterone regulation signature in the 94th percentile 
(empirical p-value=0.058). All the code for analysis is available upon request. 
 
Explant tissue experiments 
Clinical samples 
Breast tumour samples and relevant clinical data were obtained from women 
undergoing surgery at the Burnside Private Hospital, Adelaide, South Australia, with 
informed, written consent. This study was approved by the University of Adelaide 
Human Research Ethics Committee (approval numbers: H-065-2005; H-169-2011). 
Patients enrolled in the UT Southwestern study provided written consent allowing the 
use of discarded surgical samples for research purposes according to an Institutional 
Board-approved protocol. Tumours were obtained from the UT Southwestern Tissue 
Repository under Institutional Review Board (IRB) (STU 032011-187). 
 
Tissue collection and processing  
Excised tissue samples were delivered to the laboratory on ice within one hour 
following surgery and washed in culture medium comprised of phenol red-free RPMI 
(SAFC Biosciences, Kansas, USA), 200 mM glutamine (SAFC Biosciences), 1x 
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antibiotic-antimycotic (Sigma-Aldrich, St Louis, MO, USA), 10 µg/ml insulin 
(Sigma-Aldrich), and 10 µg/ml hydrocortisone (Sigma-Aldrich). Breast tumour 
tissues were cultured ex vivo as previously described28. In brief,  tumour pieces 
(explants) were pre-incubated on gelatine sponges (3-4 per sponge) for 36 hours in 
culture media containing 10% FCS, followed by treatment with hormones as 
indicated in culture media containing 10% steroid depleted FCS. The conditions used 
were: vehicle, estradiol (10 nM), R5020 (10 nM) and the combination of estradiol and 
R5020 (both at 10 nM) with hormone treatment conducted for 48 hours.  
Representative pieces of tissue were fixed in 4% formalin in phosphate-buffered 
saline (PBS) at 4ºC overnight and subsequently processed into paraffin blocks. 
Sections (2 μm) were stained with hematoxylin and eosin and examined by a 
pathologist to confirm and quantify the presence/proportion of tumour cells.  
 
Immunohistochemistry 
Primary antibodies to detect ER (ID5 1:300; DAKO #M7047, Glostrup, Denmark), 
PR (1:1000, Leica #NCL-PgR-AB, Wetzlar, Germany) or Ki67 (MIB1 1:400; DAKO 
#M7240 Glostrup, Denmark) were used in conjunction with a 1:400 dilution of a 
biotinylated anti-mouse secondary antibody for 30 min (DAKO #E0433, Glostrup, 
Denmark) followed by incubation with HRP-conjugated streptavidin (DAKO #P0397, 
Glostrup, Denmark). Visualization of immunostaining was performed using 3,3-
Diaminobenzidine (Sigma #D9015), as previously described36. 
 
Image capture and quantification of Ki67 immunostaining 
Slides were scanned at 40X magnification (NanoZoomerTM Microscopy System, 
Hamamatsu, Japan) and the digitized images edited to exc lude non-glandular 
structures. A minimum of 10 high-resolution images from Nanozoomer files of all 
segments were recorded. Brown pixels (Ki67) and blue pixels (haematoxylin) were 
extracted from each image using Adobe Photoshop and the Colour Range tool and a 
fuzziness factor of 20. Extracted pixels were converted to greyscale format and a 
consistent threshold applied. Absolute numbers and proportion of Ki67-positive cells 
were determined using ImageJ software and the Analyse Particles tool with a 
circularity index of 0.2-1. An average of 14,000 cells were quantified per sample. 
Accuracy of automatic quantification was determined using an independent set of 
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images that were assessed by an offsite independent observer who manually counted 
Ki67-positive and Ki67-negative cells in high-resolution images systematically 
sampled from an individual patient sample (containing  >6,500 cells).  Identical 
images were analysed by automatic quantification with consistency between manual 
and automatic counting of >95%. A linear mixed-effects model of percentage Ki67-
positive cells versus type of treatment, adjusting for clustering on patient, was used to 
assess statistical significance. 
 
Immunofluorescence  
5μm sections were cut and adhered to Superfost UltraPlus slides (Menzel-Glasser 
Braunscweig, Germany) and baked on a warm block at 60oC for 1 hour. Sections 
were dewaxed in 3 x 5 min immersions of xylene followed by 3 x 5 min immersions 
in 100% ethanol. Sections were rehydrated in 2 x 5 min immersions in 70% ethanol 
followed by 2 x 5 min immersions in distilled H2O. Next, antigen retrieval was 
performed in 600 mL of 1 mM Na-EDTA (pH 8.0) by heating in an 800W microwave 
until boiling (approximately 5 min), allowing slides to stand for 5 min before 
microwaving at 50% power for an additional 5 min. Slides were allowed to cool in 
antigen retrieval buffer for 60 min before transferring to PBS for 5 min. Sections were 
encircled with a wax pen and primary antibody diluted in PBS with 10% normal goat 
serum was applied overnight at 4oC (rat anti-ER – 1:100 (Abcam #ab46186); mouse 
anti-PR – 1:500 (Dako #NCL-PgR-AB); rabbit anti-Ki67 – 1:100 (Abcam #ab16667). 
Sections were washed twice for 5 min in PBS, followed by incubation with secondary 
antibody diluted (all at 1:400) in PBS with 10% normal goat serum for 30  min at 
room temperature (goat anti-rat Alexa488 (#A11006); goat anti-mouse Alexa569 
(#A11031); goat anti-rabbit Alexa647, (#A21246.), Life Technologies). Sections were 
washed twice for 5 min in PBS, followed by incubation with 1 nM DAPI diluted in 
PBS for 2 min at room temperature. Sections were mounted under DAKO fluorescent 
mounting media (#S3023) and each fluorescent channel captured separately using a 
Zeiss LSM700 confocal microscope.   
 
PgR copy number analysis  
Matched DNA and RNA were extracted for 1,980 tumours. The copy number analysis 
was performed using the Affymetrix SNP 6.0 platform. The arrays were first pre-
processed and normalised using CRMAv237 method from the aroma.affymetrix R 
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package. For each array, allelic-crosstalk calibration, probe sequence effects 
normalisation, probe- level summarisation and PCR fragment length normalisation 
were performed. Then the intensities were normalised against a pool of 473 normals 
for those samples that had no matched normal or against their matched normal when 
available. The log-ratios were segmented using the CBS algorithm38 in the DNAcopy 
Bioconductor package. Then, callings into five groups (homozygous deletion, 
heterozygous deletion, neutral copy number, gain and amplification), were made 
using thresholds based on the variability of each sample and their proportion of 
normal contamination. Then, samples were classified as PgR loss if they showed any 
type of loss in any part of the gene. 
 
RNA analysis was performed using Illumina HT-12 v3 platform and analysed using 
beadarray package39. BASH40 algorithm was employed to correct for spatial artifacts. 
Bead- level data was summarized and a selection of suitable probes based on their 
quality was done using the re-annotation of the Illumina HT-12v3 platform41. The 
samples were classified into the five breast cancer subtypes using PAM5042 and the 
10 integrative clusters29. Two-sided t-tests were performed between expression values 
and loss of PGR to determine significance. Kaplan-Meier estimates and log-rank tests 
were obtained using the survival R package (http://CRAN.R-
project.org/package=survival). Comparison of the expression of the stringent 
progesterone/R5020 induced or repressed genes in samples with PGR lost and not lost 
was performed averaging the expression of all the genes and running a two-sided t-
test. 
 
Xenograft experiments 
Mice were maintained, and regulated procedures performed, according to UK Home 
Office project license guidelines. Sample size was calculated using a combination of 
the NC3Rs recommended Resource Equation method, and also prior knowledge of 
the experimental variability of breast cancer cell line xenografts in NSG animals. All 
in vivo experiments were performed using age matched female NOD/SCID/IL2Rg-/- 
(NSG) mice and all experiments were blinded. Animals were selected using the 
following criteria: sex (female) and age matched (where possible litter mates were 
used) to reduce variability; only animals in excellent health used (verified pathogen 
free and in excellent physical health); all animals were certified as NSG strain. 
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Animals were randomly assigned to treatment groups using a random number 
generator at the beginning of the study. Briefly, mice were injected subcutaneously 
into the No 4 inguinal mammary fat pad with a suspension of 105 MCF7-Luc2/YFP 
cells in 50% growth factor reduced MatrigelTM (BD Biosciences). Where appropriate, 
90 day slow-releasing 17b-estradiol (0.72 mg/pellet) and/or progesterone (10 
mg/pellet) hormone pellets (Innovative Research of America) were implanted 
subcutaneously in recipient mice. Tumour growth was monitored using regular 
bioluminescent imaging (IVIS) and caliper measurement. Data were analysed using 
the GraphPad Prism statistical software package. Standard deviations within groups 
were similar and substantially less than the variation between the treatment groups. 
Sample size was determined by a pilot experiment with smaller number of mice. Mice 
used for all experiments were age and litter matched (3 months) to reduce variability. 
15 mice were injected with tumours and then 5 mice were selected at random for each 
treatment arm. Treatments were blinded using coded cages. Mice were regularly 
assessed for health and endpoint was determined on regulatory guidelines for tumour 
size. 
 
For Tamoxifen experiments, age matched female NSG mice were injected as above 
with either 105 MCF7-Luc2/YFP cells or 107 T-47D-Luc2/mStrawberry cells in 50% 
growth factor reduced MatrigelTM (BD Biosciences). Concomitantly, a 90 day slow-
release 17b-estradiol (0.72 mg/pellet) (Innovative Research of America) was 
implanted subcutaneously. One week later either 90 day slow-release progesterone 
(10 mg/pellet) hormone or placebo pellets (Innovative Research of America) were 
implanted subcutaneously, and Tamoxifen/Vehicle administration was commenced. 
100 µL Tamoxifen (5 mg/mL) or vehicle (sterile filtered corn oil) were administered 
i.p. to a schedule of 3 days dosing/1 day rest for a total duration of 4 weeks (MCF7) 
or 8 weeks (T-47D). Tumour sizes were monitored as above. Each treatment arm 
consisted of 10 tumours. 
 
For ovariectomisation experiments, age matched female NSG mice were injected as 
before with 105 MCF7-Luc2/YFP cells in 50% growth factor reduced MatrigelTM (BD 
Biosciences), and 90 day slow-release 17b-estradiol (0.72 mg/pellet) and/or 
progesterone (10 mg/pellet) and/or placebo hormone pellets (Innovative Research of 
America) were implanted subcutaneously in recipient mice. Concomitantly, 
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ovariectomisation was performed. Tumour sizes were monitored as above for 7 weeks. 
Each treatment arm consisted of 10 tumours. 
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Figure Legends 
Figure 1. PR is a novel ER  interacting protein following progesterone 
treatment. MCF-7 and T-47D breast cancer cells were SILAC labelled, treated with 
hormones and harvested for RIME (endogenous protein purification-mass 
spectrometry) of either PR (a) or ER (b). Differential proteins identified in both cell 
lines are plotted and all proteins are provided in Supplementary table 1. The axes 
represent log fold change. c. Co-IP validation of PR interactions with ER. Both PR 
isoforms interact with ER. d. Model showing possible mechanisms of interplay 
between PR and ER (ER)-co-factor complex.  
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Figure 2. Progesterone redirects estrogen-stimulated ER  binding events to 
novel chromatin loci and transcriptional targets. ChIP-seq for ER, PR and the 
co-activator p300 in T-47D cells grown in estrogen-rich media and treated with 
progesterone or R5020. a. Example binding region of a progesterone/R5020 induced 
ER, PR and p300 binding event. b. Heatmap of ER, PR and p300 ChIP-seq data 
from T-47D cells after 3hr of progesterone treatment. The heatmap is shown in a 
horizontal window of -/+ 5kb. Also shown are the enriched motifs within each 
category. c. Overlap between progesterone- induced ER, PR and p300 binding sites, 
representing only the progestogen-induced ER binding events. d. RNA-seq was 
performed after progesterone or R5020 treatment for 3hr under estrogenic condition 
(control). GSEA analysis was conducted, comparing progestogen- induced transcripts 
with progestogen-induced ER binding events within T-47D cells.   
 
Figure 3. Progesterone treatment inhibits ER+ tumour progression. a. MCF-7-
Luciferase cells were implanted in NSG mice with control, estrogen (E2) pellets or 
estrogen plus progesterone (E2 + Prog) pellets (n = 10). b. Graphical representation of 
tumour formation, as assessed by bioluminescence. c. ER ChIP-seq was conducted 
on randomly chosen (n = 6) xenograft tumours from ovariectomised NSG mice 
treated with estrogen alone or estrogen plus progesterone. MA plot representing 
changes in ER binding. d. Proliferative responses (Ki67 staining) of primary breast 
cancer tissues cultured ex vivo with estrogen (E2) or progestin (R5020) alone or both 
in combination (n = 14 samples/treatment; except for vehicle (n = 11) and R5020 
treatments (n =12)). The p-value was calculated using a linear mixed effect analysis. e. 
Representative images of Ki67 immunostaining in ex vivo cultured breast tumour 
tissue sections from two patients (scale bar = 100um). f. MCF-7 xenografts were 
grown in NSG mice in the presence of estrogen pellets. Mice were treated with 
vehicle, tamoxifen, progesterone or tamoxifen plus progesterone and normalised 
tumour volume is shown. The data was analysed using a t-test and the error bars 
represent +/- SEM. 
 
 
Figure 4. The PgR genomic locus undergoes copy number loss in ER+ breast 
cancer. a. METABRIC breast cancers (1,937 in total) were assessed for copy number 
 24 
change in the PgR genomic locus. b. Correlation between PR mRNA levels and copy 
number status within all ER+ cases. The estimate of differences is 0.3551, 95% 
confidence interval: [0.244, 0.463]. c. Kaplan Meier curve showing breast cancer 
specific survival in all ER+ cases. Cox model analysis: Hazard ratio = 1.46 [1.156, 
1.843]. d. Changes in ER mRNA levels in luminal B tumours within the 
METABRIC cases. The estimate of differences is 0.4436, 95% confidence interval: 
[0.269, 0.618]. e. The expression levels of the stringent progestogen- induced or 
repressed genes from the cell lines cultured under estrogenic conditions, were 
assessed in the ER+ METABRIC tumours. Relative fraction of tumours with PgR 
CNA events within molecular subtypes, based on the PAM50 gene expression profile  
(f) and the ten integrative clusters (g).  
 
 
Extended data figure legends 
 
Extended data figure 1. Protein purification of ER  and PR interacting proteins, 
using RIME, following treatment with a synthetic progestin. T-47D and MCF-7 
breast cancer cells were grown in SILAC-isotope containing media and treated with 
either vehicle control or R5020, a synthetic progestin for 3hr. PR (a) or ER (b) 
RIME was conducted and the proteins that were quantitatively enriched in both cell 
lines are shown. Only proteins that were enriched with a FDR < 1% were included. c. 
Peptide coverage of the PR protein following ER RIME in T-47D cells. The 
identified peptides are highlighted and one of the peptides covers the ‘Bus’ region 
representing the PR-B isoform. d. Comparison of binding at different time points and 
treatment of MCF-7 breast cancer cells with progesterone. ER ChIP-seq at 3hr and 
24hrs results in comparable binding. Correlation between Progesterone (PG) and 
R5020 (RO) at 3 and 24 hrs. e. MCF-7 cells were grown in estrogen rich complete 
media and treated with progesterone or vehicle control for 3hr. ER ChIP was 
conducted and peaks that occurred in at least two of three independent replicates were 
considered. Venn diagram showing the changes in ER binding following 
progesterone treatment of MCF-7 cells. f. Uncropped Western blots from Figure 1c. 
 
 25 
Extended data figure 2. Clustering of  ER , PR, and p300 ChIP-seq experiments 
in two ER+ cell lines. For each experiment, all binding sites identified as 
overlapping in at least two samples are merged and retained, and no rmalised read 
counts computed at each site for each sample. a. Clustering correlation heatmaps, 
based on Pearson correlations read scores (with replicate numbers in the labels), show 
good reproducibility between replicates and similarity of natural and synthetic 
hormone treatments. b. PCA plots showing the two most significant principal 
components (with samples labeled with treatment type: “C” for full-media control 
conditions, “P” for progesterone, and “R” for R5020). The data from the two cell lines 
is shown.  
 
Extended data figure 3. ER inding in single hormone conditions. a. T47-D or 
MCF-7 (b) cells were hormone deprived and treated with vehicle control, estrogen 
alone or progesterone alone. ER ChIP-seq was conducted and we assessed the 
binding at the regions previously shown to be reprogrammed by estrogen plus 
progesterone. The ER reprogramming data under both estrogen and progesterone 
conditions in the T-47D cells is from Figure 2b. In the absence of estrogen, 
progesterone does not induce ER binding. In the absence of progesterone, estrogen 
does not induce ER binding to the locations shown to acquire reprogrammed ER 
binding events under dual hormone conditions. 
 
Extended data figure 4. Validation of binding and gene expression changes. a. 
Validation of dependence on PR for ER binding and overlap between ER binding 
and FoxA1 binding. T-47D cells were grown in full, estrogen-rich media and 
transfected with siControl or siRNA to PR. ER ChIP was conducted followed by 
qPCR of several novel ER binding events only observed under progesterone 
treatment conditions. In the absence of PR, ER is not able to associate with the 
progesterone-induced binding sites. The figure represents one biological replicate of 
three competed replicates and the error bars represent standard deviation of the 
technical ChIP-PCR replicates. b. Venn diagram showing the ER binding events 
that were conserved in T-47D cells (i.e. not altered by progesterone when compared 
to estrogen alone) and the ER binding events that were reprogrammed by 
progesterone treatment, when overlapped with FoxA1 ChIP-seq data from T-47D 
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cells. The FoxA1 ChIP-seq data from T-47D cells was from Hurtado, et al, Nature 
Genetics, 2011, 43:27-33. c. Differential gene changes in MCF-7 and T-47D cells 
following treatment with progesterone or R5020 for 3hr. Heatmap showing gene 
changes relative to matched controls. Eight replicates were included. d. Table 
showing the differentially regulated genes in the two cell lines and in the two 
treatment conditions. e. Overlap between genes regulated by progesterone (in both 
cell lines) and gene regulated by the synthetic progestin R5020 (in both cell lines).  
 
Extended data figure 5. Analysis of gene expression changes and generation of 
gene signature. a. RNA-seq was conducted after progesterone or R5020 treatment for 
3hr. GSEA analysis was conducted on progesterone/R5020 repressed genes with lost 
ER binding events observed in T47-D cells. The progesterone-decreased ER 
binding regions correlate with progesterone down-regulated genes. b. Kaplan Meier 
survival curve in 1,959 breast cancer patients based on a gene signature derived from 
the progesterone regulated genes and progesterone regulated ER binding events. For 
a gene to be considered it was differentially regulated by progesterone/progestin (as 
measured by RNA-seq) and the gene had a differentially regulated ER binding event 
within 10kb of the transcription start site. This resulted in 38 genes (c). d. 
Performance of progesterone induced gene signature at separating based on survival 
over 392 patients in top or bottom 10% of expression compared to null distribution of 
p-values computed using 1000 randomly selected 38-gene signatures. e. Copy number 
alterations on chromosome 11 in T-47D and MCF-7 cells. Green is copy number 
neutral, blue is copy number loss and red is copy number gain. T-47D cells have an 
amplification of the chromosome 11 region encompassing the PgR gene and MCF-7 
cells have a copy number loss of this genomic region. 
 
Extended data figure 6. PR inhibits cell line growth and progesterone inhibits T-
47D xenograft growth. a. MCF-7 cells were transfected with control vector, PR-A or 
PR-B expressing vectors. Western blotting confirmed the expression of the 
appropriate PR isoform. b. Growth was assessed following estrogen plus progesterone 
treatment. The graph represents the average of three independent biological replicates 
and the error bars represent standard deviation. c. Assessment of MCF-7 xenograft 
tumour growth by physical measurement of tumour volume. Ten tumours for each 
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condition (two in each of five mice per condition) were included. The data was 
analysed using a t-test and the error bars represent +/- SEM. d. T-47D xenografts 
were established in NSG mice. Ten tumours for each condition (two in each of five 
mice per condition) were included. All were grown in the presence of estrogen (E2) 
pellets and subsequently supplemented with vehicle, progesterone, tamoxifen or 
tamoxifen plus progesterone. Normalised tumour growth is shown. The data was 
analysed using a t-test and the error bars represent +/- SEM. e. Final T-47D xenograft 
tumour volumes are shown. f. Final T-47D xenograft tumour volumes plotted 
graphically. 
 
Extended data figure 7. Histological analysis of xenograft tumours and ChIP-seq 
from xenograft tumours in ovariectomised mice. a. Histological analysis of MCF-7 
xenograft tumours in untreated, estrogen or estrogen plus progesterone conditions. 
Tumours were taken from 25 day treated conditions. The human xenograft cells 
expressed GFP, permitting discrimination between human tumour cells and mouse 
host cells. MCF-7 xenograft experiment in ovariectomised mice. b. In order to map 
ER binding events by ChIP-seq in MCF-7 xenograft tumours, we repeated the 
experiment in ovariectomised mice to eliminate any issues related to the endogenous 
mouse progesterone. Ten tumours for each condition (two in each of five mice per 
condition) were included. Growth of xenograft tumours under different hormonal 
conditions, Control, estrogen alone (E2) and estrogen plus progesterone (E2 + Prog). 
The data was analysed using a t-test and the error bars represent +/- SEM. c. ChIP-seq 
for ER and PR were conducted in six matched tumours from each hormonal 
condition. Also included were two tumours from no hormone conditions. Correlation 
heatmap of all samples.  
 
Extended data figure 8. Primary tumours cultivated as ex vivo explants shown 
response to progesterone. Representative images of primary breast cancer explant 
tissue sections treated with vehicle, estrogen (E2), the progestin R5020 or estrogen 
plus progestin (E2 + R5020). These sections were probed with anti-Ki67 (brown) to 
label proliferating cells (a) or Haematoxylin and Eosin (b) . Each image is of a single 
tissue segment from a selection of 3-4 sections per sample treatment. Scale bar = 
100mm. c. Confocal microscopy images (representative fields from each of the 
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triplicate fragments) of a representative primary breast cancer explant tissue treated 
with vehicle, estrogen (E2), the progestin R5020 (Progestin) or estrogen plus 
progestin (E2 + R5020) and probed with anti-ER (green), anti-PR (red) and anti-
Ki67 to assess proliferating cells (blue). 
 
Extended data figure 9. Analysis of PgR copy number loss in the METABRIC 
cohort. a. Kaplan Meier analysis of breast cancer specific survival within the 
METABRIC cohort. Only within luminal A tumours (based on PAM50 gene 
expression signature), tumours were stratified based on copy number loss of PgR or 
not. In total 19% of luminal A tumours contain a copy number loss of the PgR 
genomic locus and these patients have a poorer clinical outcome. b. All ER+ cases 
were stratified based on PgR copy number status, showing tumours with heterozygous 
and homozygous deletions separately. c. Chromosome 11 in tumours with neutral or 
gained PgR versus those with copy number loss of the PgR gene (defined by line). d. 
Chromosome 11 copy number status between ER positive and negative tumours. e. 
Visual representation of all ER+ tumours with a copy number alteration at the PgR 
genomic locus, showing the copy number changes relative to the PgR gene 
(highlighted below) and the surrounding ~2.2 Mb of genomic sequence.  
 
Extended data figure 10. Validation of genomic copy number loss in the PgR 
gene in an independent dataset. a.  TCGA ER+ breast cancers were assessed for 
copy number changes in PgR. The number of tumours in each category, based on 
copy number changes. Only included were ER+ breast cancers. b. Correlation 
between PR mRNA levels and copy number status in all luminal breast cancers within 
the TCGA cohort. The heterozygous and homozygous deletions are combined. c. 
Frequency of copy number alterations across entire genome in TCGA breast cancer 
cohort, stratified based on subtype using PAM50 signature. Chromosome 11, which 
encompasses PgR gene is highlighted and the frequency of copy number loss of the 
PgR genomic region is provided. d. Copy number changes on chromosome 11 within 
the METABRIC cohort, based on subtype stratification (PAM50 signature). 
 
Supplementary Table 1 
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This Supplementary table contains all RIME proteomic SILAC data from Figures 1a, 
Figure 1b and Extended data figure 1. 
 
Supplementary Table 2 
Peak numbers following ER, PR and p300 ChIP-seq in T-47D and MCF-7 cell lines. 
The number of peaks for the different conditions are shown and these include 
estrogen, estrogen plus progesterone and estrogen plus R5020 treatment. Also 
included are the common peaks observed under both estrogen plus progesterone and 
estrogen plus R5020 conditions.  
 
Supplementary Table 3 
Enriched pathways based on the ER binding events induced by progesterone and 
R5020. Shown are the enriched pathways that occur in both T-47D and MCF-7 cells. 
The values represent the Odds ratio. 
